Equities
  • Price (USD)119.90
  • Today's Change5.48 / 4.79%
  • Shares traded4.17m
  • 1 Year change-1.15%
  • Beta1.4373
Data delayed at least 15 minutes, as of May 29 2020 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Revenue in USD (TTM)5.30bn
  • Net income in USD2.37bn
  • Incorporated1992
  • Employees3.08k
  • Location
    Alexion Pharmaceuticals Inc121 Seaport BlvdBOSTON 02210-2050United StatesUSA
  • Phone+1 (475) 230-2596
  • Fax+1 (203) 271-8198
  • Websitehttp://alexion.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALXN:NSQ since
announced
Transaction
value
Achillion Pharmaceuticals IncDeal completed16 Oct 201916 Oct 2019Deal completed14.40%1.23bn
Data delayed at least 15 minutes, as of May 29 2020 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Merck KGaA18.62bn1.72bn14.80bn57.45k28.912.473.900.79473.573.6538.5942.680.4021.974.54294,130.003.724.195.065.5562.5965.009.2610.490.61047.400.426910.238.877.2920.632.2310.345.39
Shionogi & Co Ltd3.11bn1.13bn18.39bn5.23k16.202.8314.195.92392.73392.731,083.572,250.130.43151.425.98--15.6214.7217.4916.6983.0880.0336.1930.356.14----25.21-7.914.10-8.6422.45-2.9214.65
Otsuka Holdings Co Ltd13.19bn1.35bn25.17bn32.99k18.551.5112.011.91262.26262.262,622.243,217.360.55232.723.9843,096,600.005.794.237.055.2068.2366.8110.487.991.86--0.12252.458.07--54.14------
Alexion Pharmaceuticals, Inc.5.30bn2.37bn26.48bn3.08k11.302.269.655.0010.6110.6123.6553.130.32940.78654.481,718,203.0014.775.3415.785.7592.0690.6644.8318.833.8275.090.17370.0020.8117.4411,294.7929.634.55--
Astellas Pharma Inc12.07bn1.81bn33.07bn16.24k18.452.7613.612.74103.77103.77692.47694.030.61711.833.77--9.2710.5513.3914.0478.7376.9515.0215.090.8971808.070.269235.72-0.42140.8448-12.087.54-0.82115.92
Data as of May 29 2020. Currency figures normalised to Alexion Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

38.77%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202016.10m7.25%
BlackRock Fund Advisorsas of 31 Mar 202011.41m5.14%
SSgA Funds Management, Inc.as of 31 Mar 202011.08m4.99%
Fidelity Management & Research Co. LLCas of 31 Mar 202010.91m4.91%
Baker Bros. Advisors LPas of 14 May 20208.94m4.03%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20208.54m3.85%
ClearBridge Investments LLCas of 31 Mar 20206.55m2.95%
Columbia Management Investment Advisers LLCas of 31 Mar 20205.35m2.41%
Renaissance Technologies LLCas of 31 Mar 20203.76m1.70%
Swedbank Robur Fonder ABas of 31 Mar 20203.45m1.55%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.